TY - JOUR
T1 - Regenerative medicine build-out
AU - Terzic, Andre
AU - Pfenning, Michael A.
AU - Gores, Gregory J.
AU - Harper, C. Michel
N1 - Publisher Copyright:
© AlphaMed Press 2015.
PY - 2015/12
Y1 - 2015/12
N2 - Regenerative technologies strive to boost innate repair processes and restitute normative impact. Deployment of regenerative principles into practice is poised to usher in a new era in health care, driving radical innovation in patient management to address the needs of an aging population challenged by escalating chronic diseases. There is urgency to design, execute, and validate viable paradigms for translating and implementing the science of regenerativemedicine into tangible health benefits that provide value to stakeholders. A regenerative medicinemodel of care would entail scalable production and standardized application of clinical grade biotherapies supported by comprehensive supply chain capabilities that integrate sourcing and manufacturing with care delivery. Mayo Clinic has rolled out a blueprint for discovery, translation, and application of regenerative medicine therapies for accelerated adoption into the standard of care. To establish regenerative medical and surgical service lines, the Mayo Clinic model incorporates patient access, enabling platforms and delivery. Access is coordinated through a designated portal, the RegenerativeMedicine Consult Service, serving to facilitate patient/provider education, procurement of biomaterials, referral to specialty services, and/or regenerative interventions, often in clinical trials. Platforms include the RegenerativeMedicine Biotrust and Good Manufacturing Practice facilities for manufacture of clinical grade products for cell-based, acellular, and/or biomaterial applications. Care delivery leverages dedicated interventional suites for provision of regenerative services. Performance is tracked using a scorecard system to inform decision making. The Mayo Clinic roadmap exemplifies an integrated organization in the discovery, development, and delivery of regenerative medicine within a growing community of practice at the core of modern health care.
AB - Regenerative technologies strive to boost innate repair processes and restitute normative impact. Deployment of regenerative principles into practice is poised to usher in a new era in health care, driving radical innovation in patient management to address the needs of an aging population challenged by escalating chronic diseases. There is urgency to design, execute, and validate viable paradigms for translating and implementing the science of regenerativemedicine into tangible health benefits that provide value to stakeholders. A regenerative medicinemodel of care would entail scalable production and standardized application of clinical grade biotherapies supported by comprehensive supply chain capabilities that integrate sourcing and manufacturing with care delivery. Mayo Clinic has rolled out a blueprint for discovery, translation, and application of regenerative medicine therapies for accelerated adoption into the standard of care. To establish regenerative medical and surgical service lines, the Mayo Clinic model incorporates patient access, enabling platforms and delivery. Access is coordinated through a designated portal, the RegenerativeMedicine Consult Service, serving to facilitate patient/provider education, procurement of biomaterials, referral to specialty services, and/or regenerative interventions, often in clinical trials. Platforms include the RegenerativeMedicine Biotrust and Good Manufacturing Practice facilities for manufacture of clinical grade products for cell-based, acellular, and/or biomaterial applications. Care delivery leverages dedicated interventional suites for provision of regenerative services. Performance is tracked using a scorecard system to inform decision making. The Mayo Clinic roadmap exemplifies an integrated organization in the discovery, development, and delivery of regenerative medicine within a growing community of practice at the core of modern health care.
UR - http://www.scopus.com/inward/record.url?scp=84949649498&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949649498&partnerID=8YFLogxK
U2 - 10.5966/sctm.2015-0275
DO - 10.5966/sctm.2015-0275
M3 - Article
C2 - 26537392
AN - SCOPUS:84949649498
SN - 2157-6564
VL - 4
SP - 1373
EP - 1379
JO - Stem Cells Translational Medicine
JF - Stem Cells Translational Medicine
IS - 12
ER -